Table 1.
Demographic and clinical characteristics.
| Characteristics | Total Population (n = 102) |
|---|---|
| Age, median [range] (years) | 40.2 [21.1–72.7] |
| Females, n (%) | 64 (62.7) |
| Time since first MS symptoms, median [range] | 8.6 [0.2–35.7] |
| MS phenotype, n (%) | |
| Relapsing–remitting | 82 (80.4) |
| Secondary progressive | 14 (13.7) |
| Primary progressive | 6 (5.9) |
| EDSS score, median [range] | 2.5 [1–8.0] |
| DMT, n (%) | |
| None | 5 (4.9) |
| First-line therapies | 16 (15.7) |
| Fingolimod | 13 (12.7) |
| Cladribine | 15 (14.7) |
| Natalizumab | 7 (6.9) |
| Ocrelizumab | 16 (15.7) |
| Rituximab | 12 (11.8) |
| Alemtuzumab | 18 (17.6) |
| SARS-CoV-2 vaccine, n (%) | |
| BNT162b2 (Pfizer, New York, NY, USA/BioNTech, Mainz, Germany) | 72 (70.6) |
| mRNA-1273 (Moderna, Cambridge, MA, USA) | 20 (19.6) |
| AZD1222 (AstraZeneca, Cambridge, UK) | 7 (6.9) |
| JNJ78436735 (Johnson & Johnson, New Brunswick, NJ, USA) | 3 (2.9) |
DMT: disease modifying therapy; EDSS: expanded disability status scale; MS: multiple sclerosis.